MedTrace Logo

Salt Sensitivity Hypertension and Lens Opacities

NCT03385070 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 429

Last updated 2017-12-29

No results posted yet for this study

Summary

Salt-sensitive hypertension (SSH) accounts for about the half of all Hypertension (HT) cases .In SSH, Na+/K+-ATPase activity is impaired. Impaired Na+/K+-ATPase activity in the lens epithelium results in cortical opacities in the peripheral equator of the lens.

This study analyzed 305 patients with hypertension aged between 40 and 80 years and 124 non-HT controls. A total of 163 patients with HT who were admitted to the emergency service at least once with a minimum increase of 10% in their systolic and diastolic blood pressure after consuming salted food met the eligible criteria for HT and were included in the SSH group. A total of 142 patients who were previously diagnosed with HT but had no previous history were considered non-SSH. Two researchers examined the presence of cortical lens opacities biomicroscopically using the diffuse, direct, Scheimpflug, and retroillumination from fundus methods.

Conditions

  • Salt Hypertension From Excess Dietary Salt
  • Lens Opacities

Interventions

DIAGNOSTIC_TEST

Lens examination

The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.

Sponsors & Collaborators

  • Kecioren Education and Training Hospital

    lead OTHER

Principal Investigators

  • Şahbender Koç, Cardiologist · Keçiören Education and Training Hospital

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-15
Primary Completion
2017-12-07
Completion
2017-12-07

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03385070 on ClinicalTrials.gov